Publications by authors named "W Mier"
Article Synopsis
- - The study examines how a monoclonal antibody (bevacizumab) interacts with silicone oils and hydrogels, revealing that exposure to silicone oils significantly decreases the antibody's functionality and causes aggregation.
- - Results show that after 24 hours in silicone oil, bevacizumab retains only 30% of its activity, leading to concerns about its clinical use during procedures that involve silicone oil tamponade.
- - Polysorbate, a common stabilizer, effectively reduces antibody aggregation, while hydrogels do not affect the functionality of the antibodies tested, making them a safer alternative for vitreous body replacement.
Antibiotic-resistant enterococci represent a significant global health challenge. Unfortunately, most β-lactam antibiotics are not applicable for enterococcal infections due to intrinsic resistance. To extend their antimicrobial spectrum, polycationic peptides are conjugated to examples from each of the four classes of β-lactam antibiotics.
View Article and Find Full Text PDFFeasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
J Nucl Med
December 2024
Article Synopsis
- Radiopharmaceutical therapies (RPTs) using fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) offer a new treatment option for patients with progressive metastatic cancers who have undergone multiple previous treatments.
- A study involving 6 patients with various types of metastatic solid tumors showed that fractionated Bi-FAPI-46 RPT was feasible and well tolerated, with no reported adverse effects.
- Initial results indicated mixed responses: one patient had a partial response, one had stable disease, while four experienced progressive disease, suggesting that while Bi-FAPI-46 RPT is promising, further research is needed to evaluate its effectiveness.
Anti-VEGF agents, e.g., bevacizumab, are used in retinal surgery, while their interaction with silicone oils and novel hydrogels remains unclear.
View Article and Find Full Text PDFOral delivery of peptide therapeutics faces multiple challenges due to their instability in the gastrointestinal tract and low permeation capability. In this study, the aim is to develop a liposomal nanocarrier formulation to enable the oral delivery of the vancomycin-peptide derivative FU002. FU002 is a promising, resistance-breaking, antibiotic which exhibits poor oral bioavailability, limiting its potential therapeutic use.
View Article and Find Full Text PDF